BridgeMD
New treatment option for Solid Tumors, Adult
Official title HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
ClinicalTrials.gov ID: NCT07396584
What this study is testing
What is HMPL-A580?
HMPL-A580 is an investigational medicine, being studied as a potential treatment for solid tumors, adult.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a first-in-human, multicenter, open-label, phase I/Ⅱa clinical study of HMPL-A580 in participants with unresectable, advanced or metastatic solid tumors.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Understood this study and are able to voluntarily sign the informed consent form (ICF);
- Male or Female, Age ≥ 18 years;
- Histological confirmed, unresectable, advanced or metastatic solid tumor
- Participants must have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors(RECIST) v1.1
- Life expectancy ≥ 12 weeks
You likely can't join if
- An established diagnosis of type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus
- Use strong inhibitors of cytochrome P450 3A4 enzyme (CYP3A4), and inhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP)...
- Major surgery within 28 days prior to the first dose of study drug
- Active infection requiring systemic treatment
- Participant has received a live within 3 months before study enrollment
- History of inflammatory gastrointestinal diseases
See the full eligibility criteria
- Understood this study and are able to voluntarily sign the informed consent form (ICF);
- Male or Female, Age ≥ 18 years;
- Histological confirmed, unresectable, advanced or metastatic solid tumor
- Participants must have at least one measurable lesion per Response Evaluation Criteria in Solid Tumors(RECIST) v1.1
- Life expectancy ≥ 12 weeks
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1
- An established diagnosis of type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus
- Use strong inhibitors of cytochrome P450 3A4 enzyme (CYP3A4), and inhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) within 5 elimination half-lives or 2 weeks (whichever is longer) before...
- Major surgery within 28 days prior to the first dose of study drug
- Active infection requiring systemic treatment
- Participant has received a live within 3 months before study enrollment
- History of inflammatory gastrointestinal diseases
- Known hypersensitivity to any component of HMPL-A580
- Pregnant (positive pregnancy test) or lactating;
The study team makes the final eligibility decision.
Where it's taking place
- Orange, California, United States
- Plantation, Florida, United States
- Tamarac, Florida, United States
- Seattle, Washington, United States
- Changsha, China
- Nanning, China
- Shanghai, China
- Wuhan, China
- Xiamen, China
- Zhengzhou, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Orange, California, United States; Plantation, Florida, United States; Tamarac, Florida, United States; Seattle, Washington, United States; Changsha, China; Nanning, China and 4 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.